Veeva Systems Inc. (VEEV) Stock Analysis

Q: What is the VEEV stock price target?

Take-profit $238.02 (+53.0% upside). Prior stop was $144.70.

Q: What are the risks of investing in VEEV?

Concentration risk — Customer: life sciences industry; Leverage penalty (D/E 1.3): -0.5; Negative momentum; Momentum score 1.9/10 — below 4.5 minimum; Death cross — 50-day MA below 200-day MA.

Q: Is VEEV overvalued or undervalued?

Veeva Systems Inc. trades at a P/E of 29.1 (forward 16.0). TrendMatrix value score: 6.3/10. Overall verdict: Sell.

Q: What do analysts say about VEEV?

39 analysts cover VEEV with a consensus score of 4.0/5. Average price target: $264.

Temp Headwind edge

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Health Information Services

Veeva Systems provides industry cloud software, data, and business consulting exclusively to the global life sciences industry, spanning Development Cloud, Quality Cloud, Commercial Cloud, and Data Cloud. Revenues are generated primarily from subscriptions to SaaS products sold... Read more

$155.52+53.0% A.UpsideScore 6.0/10#4 of 13 Health Information Services

Stop $144.70Target $238.02(analyst − 10%)A.R:R 6.2:1

Analyst target$264.46+70.1%28 analysts

$238.02our TP

$155.52price

$264.46mean

$350

Sell if holding. Momentum 1.9/10 is below the 5.0 floor at $155.52 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.3): -0.5; Concentration risk — Customer: life sciences industry. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 6.0/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 27d clear, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.

Thesis

Rewards

Strong earnings beat streak (4/4)

High-quality business

Analyst upside: 53%

Risks

Concentration risk — Customer: life sciences industry

Leverage penalty (D/E 1.3): -0.5

Negative momentum

Key Metrics

P/E (TTM)29.1

P/E (Fwd)16.0

Mkt Cap$26.0B

EV/EBITDA19.7

Profit Mgn28.4%

ROE13.9%

Rev Growth16.0%

Beta1.10

DividendNone

Rating analysts39

Quality Signals

Piotroski F8/9

Options Flow

P/C0.70bullish

IV54%elevated

Max Pain$120-22.8% vs spot

Concentration Risks(10-K Item 1A)

HIGHCustomerlife sciences industry
10-K Item 1A: 'Nearly all of our revenues are generated by sales to customers in the life sciences industry'
LOWCustomertop-10 customers28%
10-K Item 1A: 'our top 10 customers accounted for 28% of our total revenues'

Material Events(8-K, last 90d)

2026-04-20Item 5.02LOW
Josh Faddis, SVP General Counsel, intends to retire effective November 1, 2026. Will transition to part-time advisor. Veeva will appoint a successor upon his transition.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value6.315%0.94

Quality7.715%1.16

Growth6.515%0.97

Momentum1.910%0.19

Sentiment7.610%0.76

Insider Activity5.010%0.50

Peer Rank5.510%0.55

Technical Setup5.35%0.27

Risk Profile5.65%0.28

Catalyst6.55%0.33

Overall (Σ contributions)5.95

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume

0.0

Obv

1.0

Ma Position

1.0

Macd

2.9

Rsi

4.5

Volume distribution (falling OBV)Below 200-MA, MA slope -6.7%/30d — confirmed downtrend

GatesMomentum 1.9<4.5Death cross (50MA < 200MA)A.R:R 6.2 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 27d clearSEMI CYCLE PEAK CLEARSuitability: Moderate

RSI

55 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $148.05Resistance $178.67

Price Targets

$145

$238

A.Upside+53.0%

A.R:R6.2:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Momentum score 1.9/10 — below 4.5 minimum

! Death cross — 50-day MA below 200-day MA

Earnings

4/4 beats

Next Earnings2026-05-27 (27d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is VEEV stock a buy right now?

Sell if holding. Momentum 1.9/10 is below the 5.0 floor at $155.52 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.3): -0.5; Concentration risk — Customer: life sciences industry. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $144.70. Score 6.0/10, moderate confidence.

What is the VEEV stock price target?

Take-profit target: $238.02 (+53.0% upside). Prior stop was $144.70. Stop-loss: $144.70.

What are the risks of investing in VEEV?

Concentration risk — Customer: life sciences industry; Leverage penalty (D/E 1.3): -0.5; Negative momentum.

Is VEEV overvalued or undervalued?

Veeva Systems Inc. trades at a P/E of 29.1 (forward 16.0). TrendMatrix value score: 6.3/10. Verdict: Sell.

What do analysts say about VEEV?

39 analysts cover VEEV with a consensus score of 4.0/5. Average price target: $264.

What does Veeva Systems Inc. do?Veeva Systems provides industry cloud software, data, and business consulting exclusively to the global life sciences...